Deutsche Bank AG Invests $908,000 in Inhibrx Biosciences, Inc. $INBX

Key Points

• Deutsche Bank acquired 9,579 Inhibrx Biosciences shares worth approximately $908,000 during the second quarter, representing a 0.07% stake. Institutional investors collectively own 82.46% of the company.
• Inhibrx reported a quarterly loss of $2.34 per share, missing analysts’ expectations of a $2.28 loss; analysts forecast a full-year loss of $9.91 per share.
• The stock opened at $126.70, while analyst sentiment remains mixed but averages a “Moderate Buy” rating with a consensus price target of $197.50.

Deutsche Bank AG purchased a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,579 shares of the company's stock, valued at approximately $908,000. Deutsche Bank AG owned 0.07% of Inhibrx Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Persistent Asset Partners Ltd bought a new stake in shares of Inhibrx Biosciences during the 4th quarter worth approximately $27,000. Strs Ohio acquired a new position in shares of Inhibrx Biosciences during the 1st quarter worth $27,000. Public Employees Retirement System of Ohio acquired a new position in shares of Inhibrx Biosciences during the 3rd quarter worth $40,000. BNP Paribas Financial Markets lifted its position in shares of Inhibrx Biosciences by 71.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company's stock worth $64,000 after buying an additional 789 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Inhibrx Biosciences during the 4th quarter worth $66,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Inhibrx Biosciences Price Performance

Shares of NASDAQ:INBX opened at $126.70 on Tuesday. The company has a debt-to-equity ratio of 12.58, a quick ratio of 5.07 and a current ratio of 5.07. Inhibrx Biosciences, Inc. has a 52 week low of $26.19 and a 52 week high of $155.29. The firm has a market cap of $1.87 billion, a PE ratio of -14.27 and a beta of 3.51. The firm's fifty day moving average is $94.96 and its 200-day moving average is $90.96.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) earnings per share for the quarter, missing analysts' consensus estimates of ($2.28) by ($0.06). Sell-side analysts predict that Inhibrx Biosciences, Inc. will post -9.91 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. HC Wainwright assumed coverage on shares of Inhibrx Biosciences in a research report on Monday, August 24th. They set a "buy" rating and a $245.00 price objective for the company. Wall Street Zen cut shares of Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a research note on Monday, August 17th. Citigroup reiterated a "market perform" rating on shares of Inhibrx Biosciences in a report on Thursday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $197.50.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company's proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company's lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.

Want to see what other hedge funds are holding INBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source